# Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

> **NCT02127034** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 26 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics
- Drug-Drug Interaction (DDI)

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Solifenacin
- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT02127034
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02127034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02127034, "Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02127034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*